Save the Children teams up with pharma giant GSK in Africa

International development charity Save the Children is linking up with British pharmaceutical giant GlaxoSmithKline in what both sides say is a unique collaboration to save children's lives in Africa.

will provide £15 million (18 million euros, $23 million) over five years to train and fund Save the Children community projects in the and Kenya.

The charity will take a seat on a new GSK board overseeing its paediatric research and development "to accelerate progress on innovative life-saving interventions for under-fives" and widen access in the developing world, they said in a joint statement.

Save the Children admitted the tie-up would be controversial given criticism—that it once voiced—that the pharmaceutical giant limits access to healthcare in developing countries by setting the prices of its drugs too high.

"In the past Save the Children may not have embarked on a collaboration with a pharmaceutical company like GSK," admitted Justin Forsyth, chief executive of the charity's British branch.

"But we believe we can make a huge difference if we harness the power of GSK's innovation, research and global reach."

Under the partnership, GSK will look into reformulating the antiseptic , currently found in mouthwash, into a product that could be used to cleanse the umbilical cord stump on newborn babies.

Studies from South Asia suggest this could prevent up to one sixth of in high-risk areas, it said.

The pharmaceutical company will also step up the distribution of an antibiotic in powder form that could treat childhood pneumonia, which currently kills 1.4 million under-fives globally.

Save the Children's on-the-ground expertise will be vital in deciding how such products can be distributed, from the language on the packaging to the weather and conditions in the target areas, the company said.

GSK, which posted pre-tax profits of £1.41 billion for the first quarter of this year, will fund the development of the products and said it would sell them at cost price.

The deal raises questions of whether Save the Children will be obliged to promote GSK products, but Simon Wright, the charity's head of child survival in London, insisted the deal was a "fantastic opportunity" to influence where the pharma giant spends its money.

"Some of those (products) may work, some of those may not work, but we're also engaging more broadly in their research and development agenda and making sure the impact on the poorest is a key part of it," Wright told AFP.

He said GSK had "changed a lot over the last few years" in promoting access to medicines, and said charities must recognise that the private sector "has to be part of the solution".

"The idea of just staying distant from the private sector, saying, 'it's involved in grubbily making profits, we don't want to go anywhere near it'—I think those days have gone," he said.

The £15 million includes £1 million to be raised by GSK employees, and will see £9 million given to projects in DR Congo and £4 million for projects in Kenya.

Rohit Malpani, director of policy for Medecins Sans Frontieres, said: "The real understanding of how effective this partnership is, is whether or not companies like GSK put access to medicines at the heart of their business models."

Malpani said that although drugs companies had improved their pricing practices over the past decade, it was a small step from a very low base.

"People are still paying too high prices, innovation has not truly changed to benefit low-income countries," he told AFP.

add to favorites email to friend print save as pdf

Related Stories

Drugmaker GSK posts slumping Q1 profits

Apr 24, 2013

British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.

GSK unveils expansion plans in India, Nigeria

Nov 26, 2012

British drugmaker GlaxoSmithKline said it intends to increase its holdings in its Indian and Nigerian divisions, as part of a long-term strategy to expand into emerging markets, in a statement on Monday.

DR Congo 'worst place to be a mother' (Update)

May 07, 2013

The Democratic Republic of Congo has displaced Niger to gain the unenviable distinction of being the worst place in the world to be a mother, according to a new report by Save the Children.

GlaxoSmithKline says net profits drop 13% in Q1

Apr 25, 2012

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments